DLBS2411 clinical trials
Also written DLBS2411.
How each study uses DLBS2411 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2018 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses DLBS2411 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- DLBS2411 Treatment For Functional DyspepsiaCompletedPhase 3Dexa Medica GroupNCT05248802Written as DLBS2411
- Efficacy and Safety of DLBS2411 in the Management of GERDTerminatedPhase 3Dexa Medica GroupNCT03367195Written as DLBS2411
- DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic UlcersTerminatedPhase 3Dexa Medica GroupNCT02262169Written as DLBS2411
- Efficacy and Safety of DLBS2411 in Healthy VolunteersCompletedPhase 1/2Dexa Medica GroupNCT01573403Written as DLBS2411